不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于 ZUMA-7 试验的日本二线 axicabtagene ciloleucel 与标准治疗的成本-效用分析
英文原题：Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial.
查看英文原题
Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目的
从日本支付方角度，基于关键性ZUMA-7试验数据，对axicabtagene ciloleucel（axi-cel）与标准治疗（SoC；挽救性化学免疫治疗，对缓解者随后进行大剂量治疗联合自体干细胞挽救）用于成人复发/难治性大B细胞淋巴瘤（r/r LBCL）二线（2L）治疗进行成本效果分析。
材料与方法
采用三状态分区生存模型，使用来自ZUMA-7试验数据的人群和临床输入，时间范围为终生。
结果
与SoC相比，axi-cel与更高的增量质量调整生命年（2.06）和更高的增量总成本（$48,685.59/¥6.9 million）相关，导致增量成本效果比为$23,590.34/¥3.3 million每质量调整生命年。
结论
对于成人r/r LBCL的2L治疗，axi-cel是相较于SoC具有成本效果的替代治疗选择。[Box: see text]。
展开英文摘要原文
Aim: To perform a cost-effectiveness analysis comparing axicabtagene ciloleucel (axi-cel) with standard of care (SoC; salvage chemoimmunotherapy, followed by high-dose therapy with autologous stem cell rescue for responders) for second-line (2L) treatment of adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) in the pivotal ZUMA-7 trial data from a Japanese payer perspective. Materials & methods: A three-state partitioned survival model was utilized using population and clinical inputs from the ZUMA-7 trial data over a lifetime horizon.
Results: Axi-cel was associated with greater incremental quality-adjusted life-years (2. 06) and higher incremental total costs ($48,685. 59/¥6. 9 million) leading to an incremental cost-effectiveness ratio of $23,590. 34/¥3. 3 million per quality-adjusted life-years compared with SoC. Conclusion: Axi-cel is a cost-effective treatment alternative to SoC for 2L treatment of adults with r/r LBCL. [Box: see text].
论文信息
- 作者
- Tsutsué S、Makita S、Asou H、Matsuda H、Yamaura R
- 第一作者单位
- Gilead Sciences Japan, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6616, Japan.Japan
- 通讯作者单位
- IQVIA Solutions, Japan, 4-10-18 Takanawa, Minato-ku, Tokyo, 108-0074, Japan.Japan
- 期刊
- Future oncology (London, England)2024
- 原文标识
- PubMed 38861283 · DOI 10.1080/14796694.2024.2351353
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →